sh-Polypeptide-9 for Hair Regrowth

Evidence Review created on 09/26/2026 using AI4L / Opus 5.5

Also known as: sh-Polypeptide 9, Vascular Endothelial Growth Factor, VEGF, VEGF-A, Recombinant Human Vascular Endothelial Growth Factor A, rhVEGF, rh-Polypeptide-9, CG-VEGF, SpecPed VEGF

Motivation

sh-Polypeptide-9 is the cosmetic ingredient name for a lab-made copy of vascular endothelial growth factor, a human signaling protein whose natural job is to tell the body to build new blood vessels. Because a growing hair root depends on a dense web of tiny vessels around its base, the ingredient is added to hair serums and scalp injection kits sold to people with thinning hair.

Interest grew as injections of a person’s own concentrated blood platelets became popular for hair loss, and bottled copies of the same growth signals offered a standardized, blood-free alternative. Today the ingredient appears in many consumer “peptide” hair serums and in professional injection kits, almost always alongside several other growth-signal copies, vitamins and amino acids.

This review examines what the evidence shows about sh-Polypeptide-9 for regrowing scalp hair in pattern hair loss and related forms of thinning: how it is thought to work, what human studies of products containing it report, who funded and ran those studies, which risks are documented or plausible, and how it is used in practice.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

This section lists expert commentary and primary or narrative scientific sources that give a high-level overview of sh-Polypeptide-9 or of the follicle blood-supply mechanism it targets.

• The Science of Healthy Hair, Hair Loss and How to Regrow Hair - Andrew Huberman

  Explains why blood flow to hair-follicle stem cells governs growth and reviews flow-raising treatments, minoxidil, platelet-rich plasma (concentrated own-blood platelets) and microneedling (tiny-needle skin puncturing), aimed at the follicle blood supply sh-Polypeptide-9 targets.

• Hair Loss - Maureen Williams & Shayna Sandhaus

  Life Extension’s protocol reviews conventional and emerging hair-loss treatments, with sections on platelet-rich plasma injections as a source of growth factors, the therapeutic category of sh-Polypeptide-9, and on microneedling.

• #43 - Alan Bauman, M.D.: The science of male and female hair restoration - how to protect, enhance, and restore the appearance and health of the hair and scalp - Peter Attia

  Peter Attia and hair-restoration surgeon Alan Bauman discuss pattern hair loss, standard drugs and, in a dedicated segment, platelet-rich plasma injections, the growth-factor injection category that sh-Polypeptide-9 products aim to replicate without blood.

• Overview of Short Peptides for Hair Loss - Fan et al., 2026

  Narrative review of peptide hair treatments that names sh-Polypeptide-9 directly, summarizes its cell-culture effects, and notes that, like several peers, it has not shown therapeutic benefit in living animals.

Rhonda Patrick’s pattern hair loss episode touches on topical growth factors only in one brief exchange, and Chris Kresser and Lifespan.io have published no content on sh-Polypeptide-9 or growth-factor hair treatments, so none of the three is listed. Only four sources discuss the ingredient, its mechanism or its therapeutic category in depth, so four are listed rather than five.

Grokipedia

Vascular endothelial growth factor

Covers the vascular endothelial growth factor (VEGF, a blood-vessel growth signal) family that sh-Polypeptide-9 copies, including its discovery, biology and medical uses. No dedicated article exists for the cosmetic ingredient; hair growth is not discussed.

Examine

No Examine article on sh-Polypeptide-9 exists. Examine lists vascular endothelial growth factor only as a measured outcome, not as a supplement or intervention.

ConsumerLab

No ConsumerLab article on sh-Polypeptide-9 exists; the site’s search returns only unrelated recalls and news releases.

Systematic Reviews

The five systematic reviews below assess injected growth-factor and mesotherapy (repeated micro-injections into the skin) treatments for androgenetic alopecia (hereditary pattern hair loss) and their risks; none isolates sh-Polypeptide-9, which has only been tested inside multi-ingredient formulations.

• Effectiveness of minimally invasive injectable modalities in the management of androgenetic alopecia among adults-A systematic review - Kumar et al., 2024

  Sixteen studies; injectable growth-factor formulations, including sh-Polypeptide-9-containing QR678 Neo, showed benefit. Authors include QR678’s inventors, a direct financial conflict of interest.

• Injectable Therapy for Androgenetic Alopecia: A Systematic Review - Beer et al., 2026

  Thirty studies of scalp injections; peptide and multivitamin formulations were most studied, but small samples, variable protocols and short follow-up limit conclusions.

• Systematic review of mesotherapy: a novel avenue for the treatment of hair loss - Gupta et al., 2023

  Twenty-seven studies across six agent classes, including growth factors; reports benefit signals alongside unstandardized regimens and documented adverse effects.

• Current application of mesotherapy in pattern hair loss: A systematic review - Tang et al., 2022

  Twelve studies with 527 participants found mesotherapy helpful without serious side effects, but samples were small and comparisons with standard drugs scarce.

• Alopecia After Cosmetic Injection Procedures: A Review - Issa et al., 2022

  Covers the principal risk: ten reports of temporary or permanent hair loss after scalp mesotherapy and other cosmetic injections, an underreported adverse effect.

Mechanism of Action

sh-Polypeptide-9 is a bioengineered copy of human vascular endothelial growth factor A (VEGF-A), produced by fermentation in Escherichia coli bacteria.

• Vessel growth: VEGF-A binds VEGF receptor 2 (VEGFR-2, the main signaling receptor on vessel-lining endothelial cells), prompting those cells to divide, migrate and form new capillaries, and to release nitric oxide, which widens vessels.
• Follicle blood supply: During anagen (the active growth phase), follicles enlarge and the capillary network around them expands as outer root sheath cells (the follicle’s outer cell layer) raise VEGF output. In mice, extra VEGF produced larger follicles and thicker shafts; blocking it slowed growth (Yano et al., 2001).
• Follicle signaling: In co-cultured human cells, sh-Polypeptide-9 raised β-catenin (a protein in the Wnt pathway, the signaling route that keeps follicles growing) and lowered interleukin-1α (IL-1α, an inflammatory messenger), in a study with an author from hair-product maker Rottapharm-Madaus (Bassino et al., 2016).
• Competing view: Pattern hair loss is driven by dihydrotestosterone (DHT, a potent male hormone) shrinking genetically sensitive follicles. Reduced blood flow may follow this shrinkage rather than cause it, so added VEGF may not reach the root cause.
• Pharmacology: A large protein (tens of kilodaltons) that cannot cross intact skin, so delivery relies on injection or needling. It acts locally, binding tissue matrix, and is broken down by protein-cutting enzymes rather than liver CYP enzymes (cytochrome P450, the main drug-metabolizing system). Infused intravenously, recombinant VEGF-A has a terminal half-life of about 34 minutes (Eppler et al., 2002).

Historical Context & Evolution

Vascular endothelial growth factor was isolated in 1989. Its original intended use was medical: the recombinant protein was developed as “therapeutic angiogenesis” (new blood-vessel formation) to grow bypass vessels in blocked hearts and limbs. In the placebo-controlled VIVA trial, patients with angina (chest pain from poor heart blood flow) given infusions improved no more than placebo at day 60, with angina easing only at the higher dose by day 120 (Henry et al., 2003). The protein never became an approved drug.

Hair came into view through follicle biology. A 2001 mouse study showed that VEGF controls follicle size and hair-shaft thickness (Yano et al., 2001), and minoxidil, the long-standing topical hair drug, was found in cell studies to stimulate VEGF (review: Messenger & Rundegren, 2004). These findings suggested better-fed follicles might grow thicker hair.

From the late 2000s, Korean biotechnology firms, notably Caregen (maker of “CG-VEGF”), brought bioengineered growth-factor copies into cosmetics under the “sh-“ (synthetic human) ingredient-naming convention. The rise of platelet-rich plasma (PRP) injections for hair made standardized, blood-free “PRP-like” cocktails commercially attractive. A 2016 cell study tested the ingredient itself; from 2020 the inventors of the QR678 Neo injection kit published a series of clinical reports (Kapoor et al., 2020), and an independent retrospective study followed in 2024.

What changed is the delivery setting, not the underlying evidence class: the ingredient moved from failed heart medicine to cosmetic mixtures, and recent systematic reviews (Beer et al., 2026) still judge the injectable-growth-factor field as promising but low quality.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: every human study tested a multi-ingredient formulation in which sh-Polypeptide-9 is one of several growth-factor copies, so no replicated clinical endpoint belongs to the ingredient itself.

Medium 🟩 🟩

No benefit reaches Medium: even the randomized studies measuring hair outcomes tested mixtures, which makes all human evidence indirect for sh-Polypeptide-9.

Low 🟩

Denser, Thicker Scalp Hair

Scalp injections of mixtures pairing sh-Polypeptide-9 with other growth-factor copies raised hair count, density and shaft thickness in androgenetic alopecia and after transplants, and reduced telogen effluvium (stress-triggered shedding). Evidence: developer-run series, shedding study, randomized PRP comparison, developer-linked transplant trial and an independent retrospective study. The ingredient’s contribution is untested.

Magnitude: In the independent retrospective study, frontal hair density rose by about 20 hairs/cm² (hair count by about 44 hairs) over 6 months with the sh-Polypeptide-9-containing DermaHeal protocol (22 patients), whereas a second product containing the same growth-factor copy under the name rh-Polypeptide-9 (allstem, 16 younger patients) significantly improved only crown hair thickness; the authors attribute the gap to differing ingredient mixes and concentrations, patient age and injection technique. In the 2,428-patient QR678 Neo series, 12% still had a positive hair-pull test after eight sessions.

Speculative 🟨

Calmer Follicle Environment

In co-cultured human follicle and vessel cells, sh-Polypeptide-9 lowered IL-1α and raised β-catenin, signals tied to follicle inflammation and growth (Bassino et al., 2016). The basis is cell culture only.

Skin Repair and Microcirculation ⭕️ Not Central to Hair Regrowth

Suppliers market the ingredient in skin-rejuvenation products to renew small skin vessels and aid repair, bearing on skin appearance and wound healing rather than hair. The basis is mechanistic only.

Benefit-Modifying Factors

• Genetic polymorphisms: Inherited sensitivity of follicles to DHT, driven by androgen receptor gene variants, sets the pace of pattern loss; strongly androgen-driven shrinkage likely limits what added blood supply can achieve. Variants in the VEGFA gene (which encodes VEGF-A) have not been studied for response.
• Baseline biomarkers: Low ferritin (stored iron), thyroid imbalance or vitamin D deficiency cause shedding that growth-factor copies do not correct; such causes blunt apparent response until treated.
• Sex: The independent retrospective study (Stefanis et al., 2024) enrolled mostly women, and a developer-run series reported gains in women with polycystic ovary syndrome (PCOS, a hormonal disorder with excess male hormones) (Kapoor et al., 2020); no study compared men and women directly.
• Pre-existing conditions: Response requires living follicles, so early to moderate loss (Norwood-Hamilton II–V in men, Ludwig I–II in women; standard baldness grading scales) is the studied range. Scarring alopecia, where follicles are destroyed, was excluded.
• Age: In the independent retrospective study (Stefanis et al., 2024), the best-responding group had a median age near 50, suggesting benefit persists in older adults; very advanced baldness with few surviving follicles, more common with age, has not been studied.
• Delivery route: Injection into the skin gave numerically better results than derma-roller application of the same formulation (Shome et al., 2021); leave-on application is covered only by a developer-run letter comparing it with derma rolling (Shome et al., 2022).
• Concurrent standard therapy: A developer-run comparison reported better results when QR678 injections were added to 5% minoxidil solution and oral finasteride than with injections alone (Shome et al., 2021).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse events come from single-center or developer-run series of mixed formulations and isolated case reports, and no trial has recorded harms of sh-Polypeptide-9 alone.

Medium 🟥 🟥

Injection Pain and Redness

Needle-based delivery commonly causes brief pain, redness and pinpoint bleeding; the procedure, not the peptide, is the likely cause. In a developer-run comparison of 50 patients, redness and pain were more frequent with derma rolling than with injection (Shome et al., 2021). Mesotherapy reviews describe such effects as mild and short-lived (Gupta et al., 2023).

Magnitude: Pain and redness occur during and shortly after sessions and settle within hours to days; the studies report no incidence figure.

Low 🟥

Paradoxical Hair Loss and Scarring

Patchy, sometimes permanent hair loss has followed scalp mesotherapy through injection pressure, inflammation or local vessel damage (review: Issa et al., 2022; Duque-Estrada et al., 2009). Reported cases involved other injected agents; none named sh-Polypeptide-9. Most resolved partly or fully.

Magnitude: Not quantified in available studies. Only case reports and small case collections exist, so no incidence can be calculated.

Scalp Infection and Abscess

Non-sterile technique or contaminated cocktails can seed bacteria into the scalp. One report described multiple scalp abscesses with fat necrosis (fat-tissue death) and scarring requiring surgery after mesotherapy (Kadry et al., 2008). The risk reflects the procedure, not the peptide.

Magnitude: Not quantified in available studies. Only isolated case reports exist.

Forehead Swelling

Forehead swelling appeared in 14 patients after scalp mesotherapy, usually in the first two sessions, and resolved with cold compresses (Melo et al., 2022). All cases involved lidocaine (a local anesthetic); minoxidil or dutasteride may contribute.

Magnitude: Swelling lasted 1–4 days in all 14 cases; the series reports no incidence rate.

Blood-Pressure Drop With Systemic Exposure

Recombinant VEGF-A infused into the bloodstream of heart patients caused hypotension (low blood pressure) through nitric oxide-driven vessel widening (Eppler et al., 2002). Scalp doses are far lower and act locally, and hair studies report no hypotension.

Magnitude: Hypotension occurred with infusions of 17–50 ng/kg/min, and its duration tracked receptor-bound VEGF levels; the reports give no incidence figure applicable to scalp use.

Possible Promotion of Skin Cancer

VEGF feeds the blood supply of tumors, raising a theoretical concern about accelerating existing skin cancers. One scalp melanoma was reported after anti-hair-loss mesotherapy, without shown causation (Arenbergerova et al., 2018).

Magnitude: Not quantified in available studies. A single case report is the only human observation.

Speculative 🟨

Flare of Psoriasis or Similar Skin Disease

Mice engineered to overproduce VEGF in skin developed psoriasis-like inflammation (Xia et al., 2003), and VEGF-A drives psoriasis plaques (review: Chen et al., 2023). The basis is animal and mechanistic only.

Allergic or Immune Reaction

As a bacterially produced human protein, the ingredient could trigger contact allergy or antibody formation, especially when injected. No such reactions have been reported; the basis is theoretical.

Risk-Modifying Factors

• Genetic polymorphisms: No drug-metabolizing variants apply because proteases degrade the protein. Inherited melanoma risk, such as CDKN2A (a tumor-suppressor gene) mutations, heightens the theoretical tumor concern.
• Baseline biomarkers: A platelet count below 50,000/µL or an INR (international normalized ratio, a clotting-time measure) above the target range raises bleeding and bruising with injection or needling.
• Sex: Women made up most study participants, and pregnant or breastfeeding women were excluded; no sex difference in adverse events has been reported.
• Pre-existing conditions: Psoriasis, rosacea (a facial redness disorder), prior skin cancer, scalp infection, keloid tendency (overgrown scars) and poorly controlled diabetes raise flare, tumor, scarring or infection concerns.
• Age: Older scalps heal more slowly and more often carry sun damage or precancerous spots (actinic keratoses), increasing the importance of a skin check before needling.

Key Interactions & Contraindications

• Anti-VEGF cancer and eye drugs (bevacizumab, aflibercept, ranibizumab): Absolute contraindication for injected use: opposing mechanisms, with a theoretical risk of undermining anti-angiogenic cancer therapy. Use is typically deferred until treatment ends and the oncologist agrees.
• VEGF-pathway kinase inhibitors (drugs blocking growth-signal enzymes: sunitinib, pazopanib, axitinib): Absolute contraindication during cancer treatment for the same reason; the drugs also cause hair and skin changes that confound results.
• Anticoagulants and antiplatelet drugs (blood thinners: warfarin, apixaban, clopidogrel): Caution with injection or needling: more bleeding and bruising. They are not stopped without the prescriber; firm pressure for 2–5 minutes after each session limits bleeding.
• Over-the-counter pain relievers (aspirin, ibuprofen, naproxen): Caution: added bruising at injection sites. Where medically acceptable, a 3–7 day pause before sessions reduces it.
• Topical minoxidil (over-the-counter): Additive intended effect on follicle blood supply. Monitor: needling increases absorption and can cause dizziness or scalp irritation; a 24-hour gap after a session before reapplying limits this.
• Topical retinoids (vitamin A-derived skin drugs) and exfoliating acids (tretinoin, glycolic acid): Caution: more irritation and redness with needling. A 3–5 day pause before and after sessions reduces it.
• Bleeding-prone supplements (fish oil above 3 g/day, Ginkgo biloba, vitamin E above 400 IU/day): Monitor: may increase bruising with injections. A 7-day pause before sessions reduces bruising.
• Vessel-widening supplements (L-arginine, L-citrulline, niacin): Monitor: additive nitric oxide or flushing effects, relevant mainly with systemic exposure; clinically minor at scalp doses.
• Lidocaine and injected minoxidil or dutasteride: Caution: linked to forehead swelling after mesotherapy. Ice or a topical anesthetic avoids this where possible.
• Other regenerative procedures (PRP, microneedling, low-level laser therapy): Monitor: additive intended effect; stacking obscures which one helps. Staggering sessions 1–2 weeks apart clarifies response.

Populations who should avoid sh-Polypeptide-9:

• People with active cancer, or melanoma or other skin cancer of the scalp treated within the past 5 years
• People receiving anti-VEGF drugs or VEGF-pathway kinase inhibitors
• People with active scalp psoriasis, rosacea, infection or open wounds
• Pregnant or breastfeeding women (no safety data; excluded from all studies)
• For injected or needled use: platelet count below 50,000/µL, INR above the prescribed target range, or a history of keloid scarring

Risk Mitigation Strategies

• Licensed injector and sterile technique: Sealed single-use vials, 30-gauge needles and chlorhexidine scalp cleansing prevent infection and abscess.
• Lidocaine-free anesthesia: Ice for 5–10 minutes or a topical anesthetic cream in place of injected lidocaine reduces the risk of forehead swelling.
• Skin check before starting: A dermatologist examination of scalp and skin within 3 months before the first session, then every 12 months, addresses the theoretical skin-cancer concern.
• Patch test for topicals: Applying the serum to the inner forearm for 48 hours before scalp use screens for allergic reaction.
• Bleeding precautions: Pausing elective blood-thinning supplements 7 days beforehand and applying pressure 2–5 minutes after sessions limits bruising and bleeding.
• Stop rule for skin flares: Stopping at the first new scaly plaque or redness lasting more than 7 days limits psoriasis-like or rosacea flares.
• Stop rule for patchy loss: Photographing treated areas each session, and stopping for dermatology review if new bald patches appear, limits paradoxical hair loss.
• Aftercare for 24 hours: Avoiding washing, swimming and heavy sweating for 24 hours after sessions lowers infection risk.

Therapeutic Protocol

• Regenerative injection approach (DermaHeal): Powder with sh-Polypeptide-9 at a stated 10 ppm (parts per million) per growth factor, injected every 1–2 weeks for 8 sessions (Stefanis et al., 2024). Popularized by manufacturer Caregen.
• Regenerative injection approach (QR678 Neo): 1.5 mL injected into the scalp every 3–4 weeks for 8 sessions (Shome et al., 2022), or applied with a derma roller. Developed by Debraj Shome and Rinky Kapoor, Mumbai.
• Topical serum approach: Leave-on serums applied once or twice daily, often with weekly microneedling, which boosted minoxidil’s effect in a randomized trial (Dhurat et al., 2013); only a developer-run letter tested topical sh-Polypeptide-9 (Shome et al., 2022).
• Drug-based approach: Topical minoxidil and, in men, oral finasteride are the regulator-approved treatments; growth-factor protocols are used either instead of them or on top of them, as the combination data above describe.
• Time of day: Topicals are usually applied in the evening for at least 8 hours of contact before washing; injection sessions can occur any time, followed by 24 hours without washing.
• Half-life: Recombinant VEGF-A lasts about 34 minutes in blood, but it binds scalp tissue locally; protocols are therefore session-based rather than timed to blood levels.
• Single vs split dose: Each injection session delivers its full dose across the thinning area at once; for serums, once-daily versus twice-daily use has not been compared.
• Genetic polymorphisms: No genetic variant guides dose or product choice; strong family history of early baldness predicts faster progression and favors combining with drug-based therapy.
• Sex: Protocols are identical for men and women; finasteride is generally avoided in women of childbearing potential, which makes non-hormonal options more relevant for them.
• Age: Studies enrolled adults 18–73; older adults follow the same schedule, with extra time between sessions if healing is slow.
• Baseline biomarkers: Low ferritin, thyroid imbalance or vitamin D deficiency are typically corrected before starting, since uncorrected deficits mask response.
• Pre-existing conditions: For alopecia areata (autoimmune patchy hair loss), injections were studied only alongside steroid injections (Shome et al., 2022); chemotherapy-related loss was treated after chemotherapy ended.

Discontinuation & Cycling

• Course-based, not lifelong: Protocols use an 8-session induction course over 3–6 months; clinics often add maintenance sessions every 3–6 months, a schedule no trial has tested.
• Withdrawal effects: None known. Because pattern hair loss continues, gains are expected to fade gradually after stopping, although developer-run studies reported results holding at 1 year (Kapoor et al., 2020).
• Tapering: Not required pharmacologically; protocols step down naturally by widening intervals from weekly to every 2–4 weeks.
• Cycling: No evidence shows that cycling preserves effect, and no tolerance to the ingredient has been described.

Sourcing and Quality

• Ingredient identification: The label lists it as “sh-Polypeptide-9”; suppliers include Caregen (CG-VEGF), Spec-Chem (SpecPed VEGF) and PnP Biopharm.
• Protein stability: Recombinant proteins degrade with heat, light and time; injectable kits supply freeze-dried powder to reconstitute just before use, and serums need airless, refrigerated or cool storage within the expiry date.
• Concentration disclosure: Most consumer serums list sh-Polypeptide-9 near the end of the ingredient list without stating an amount; brands that state parts per million allow comparison with studied products.
• Injectable products: Quality markers are sealed, regulator-registered sterile products (for example DermaHeal HL or QR678 Neo) supplied through licensed clinics; unregistered online “meso” cocktails lack these safeguards.
• Third-party testing: No independent potency testing of sh-Polypeptide-9 exists; for injectables, a certificate of analysis including sterility and endotoxin (bacterial-residue) testing is the available quality check.

Practical Considerations

• Time to effect: Measurable changes in density and thickness appear after about 3 months of sessions; developer-run studies report further gains up to 6–12 months (Kapoor et al., 2020).
• Common pitfalls: Expecting a leave-on serum to reach follicles through intact skin; dropping effective drug therapy; using unregistered injectables; and crediting sh-Polypeptide-9 with benefits that may come from needling or co-ingredients.
• Regulatory status: sh-Polypeptide-9 is a cosmetic ingredient, not an approved hair-loss drug. Injecting it is unapproved in the United States and in the European Union; QR678 Neo holds Indian regulatory approval, according to its developers.
• Cost and accessibility: An injection course typically costs several hundred to a few thousand US dollars; serums cost far less but lack clinical data.
• Payer incentives: Insurers and national health systems generally reimburse neither growth-factor injections nor minoxidil or finasteride for hair loss, so no payer incentive favors one; the financial interests lie with product makers and clinics.

Interaction with Foundational Habits

• Sleep: None known directly: the ingredient does not affect sleep. Indirect: chronic short sleep raises stress hormones that push follicles into resting phase; 7–9 hours of sleep supports response.
• Nutrition: Indirect, potentiating: follicles regrowing under better blood supply still need protein (about 1.0–1.2 g/kg/day), iron and zinc; the ingredient depletes no nutrients. Low ferritin or crash dieting blunts response.
• Exercise: Indirect: aerobic exercise raises circulating VEGF and scalp blood flow, a complementary mechanism; the ingredient does not affect muscle growth. Heavy sweating and swimming within 24 hours after injection sessions raise infection risk.
• Stress management: Indirect: chronic stress triggers telogen effluvium through stress hormones acting on follicle stem cells; the ingredient does not alter cortisol, so stress reduction complements rather than duplicates it.

Monitoring Protocol & Defining Success

Baseline testing before the first session rules out correctable causes of shedding and documents starting hair density. It includes blood tests for iron stores, thyroid function, vitamin D and zinc, hormone tests in women with irregular cycles or acne, a blood count for anyone having injections, standardized scalp photographs, and trichoscopy (magnified scalp imaging) with hair counts at marked sites. A dermatologist skin check within the prior 3 months is typically included because of the theoretical tumor concern.

Ongoing monitoring follows a set cadence: repeat photographs and trichoscopy at 3 months (end of the 8-session course), 6 months and 12 months, then every 6–12 months during maintenance. Any abnormal baseline blood value is typically rechecked 3 months after correction.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Ferritin	70–150 ng/mL	Iron stores for hair growth	Conventional lower limit is about 15–30 ng/mL; rises with inflammation, so pair with CRP (C-reactive protein, an inflammation marker)
TSH	0.5–2.5 mIU/L	Thyroid-related shedding	TSH = thyroid-stimulating hormone; conventional range 0.4–4.5 mIU/L; pair with free T4 (thyroxine); morning draw
25-hydroxyvitamin D	40–60 ng/mL	Deficiency linked to hair loss	Conventional sufficiency starts at 30 ng/mL; no fasting needed
Zinc (serum)	90–120 µg/dL	Deficiency causes shedding	Conventional range about 60–120 µg/dL; fasting morning sample
Total testosterone and DHEA-S (women)	Testosterone 15–45 ng/dL; DHEA-S within the lower half of the age-specific range	Screens for excess male hormones	DHEA-S = dehydroepiandrosterone sulfate; test on days 2–5 of the cycle, morning
CBC with platelets	Platelets 150–400 × 10³/µL	Bleeding risk and anemia before injections	CBC = complete blood count; conventional platelet range is the same; below 50 × 10³/µL defers injections
Hair density (trichoscopy)	No established target; track change from own baseline (hairs/cm²)	Primary measure of regrowth	Same device, same tattooed or marked site, same lighting each visit
Hair shaft diameter	No established target; track change from own baseline (µm)	Measures thickening	Rising share of thick (terminal) hairs signals response
Hair-pull test	2 or fewer hairs per pull of about 60 hairs	Tracks active shedding	Conventional positive threshold is more than 6 hairs; no washing for 24 hours beforehand

Qualitative markers:

• Shedding on pillow, brush and shower drain
• Visibility of the scalp along the part and crown under standard lighting
• Hair volume and styling ease
• Scalp comfort, itch or redness between sessions
• Overall satisfaction with appearance at 3 and 6 months

Emerging Research

• Peptide serum versus minoxidil trial: A randomized trial, blinded for participants, investigators and assessors, comparing the VENEZE peptide factor serum with 2% minoxidil in 80 adults with androgenetic alopecia over 24 weeks, primary endpoint change in hair density (NCT07536100); recruiting, and the registry does not disclose whether sh-Polypeptide-9 is included.
• Needle-free delivery: Hydrogel microneedle patches loaded with VEGF and ritlecitinib regrew hair in a mouse model of androgenetic alopecia (Ding et al., 2024), a route that could solve the skin-penetration problem for topical products.
• Missing animal proof: A 2026 review notes that sh-Polypeptide-9, despite cell-culture activity, has not demonstrated therapeutic effect in living animals (Fan et al., 2026), weakening the case until such studies appear.
• Weak evidence in the parent category: A meta-analysis of growth-factor injections from patients’ own blood found density gains but high risk of bias and very large disagreement between studies (I² above 90%, a measure of inconsistency) (Alali et al., 2026).
• Isolating the ingredient: No registered trial tests sh-Polypeptide-9 alone against an identical inactive base; such a trial would determine whether it adds anything beyond needling and co-ingredients.

Conclusion

sh-Polypeptide-9 is a lab-made copy of the body’s own blood-vessel growth signal, sold in hair serums and scalp injection kits on the idea that better-fed hair roots grow thicker hair. The biology is credible: animal work ties this signal to larger hair roots, and lab studies show the ingredient acts on hair-root cells.

The human evidence is thinner than the marketing suggests. Every clinical study tested mixtures in which sh-Polypeptide-9 sits beside several other growth-signal copies and additives, and most delivered them with needles, which on their own stimulate hair. They report more and thicker hair and less shedding, but nearly all lacked an inactive-product comparison group. The largest were run by the inventors of one injection kit, and the key lab study included an author from a hair-product company. An independent study of past clinic records points the same way but is small. What the ingredient adds on its own, and whether a serum on unbroken skin reaches the hair root at all, remains unknown.

The documented risks come mainly from the injection process: brief pain and redness, occasional forehead swelling, and rare infection or patchy hair loss. Concerns that the signal could worsen psoriasis or feed an existing skin cancer rest on animal data and a single case.

For people committed to treating thinning hair, it is a plausible, generally well-tolerated add-on whose benefit rests on low-quality, commercially shaped evidence.

Top - Benefits - Risks - Protocol